Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has extended its licensing agreement with GeneGo and has added additional capability. This agreement will provide GlaxoSmithKline researchers in bioinformatics, R&D and clinical studies with global access to MetaCore, MapEditor and MetaBase.
Subscribe to our email newsletter
MetaCore is used for target identification, validation, biomarker discovery and knowledge mining. According to GeneGo, GlaxoSmithKline (GSK) will also use the platform as a repository of all types of experimental data as well as resulting analyses. MetaBase is direct access to the manually curated database of pathways, networks, ontologies, medicinal chemistry and diseases covering human, mouse and rat. MapEditor is a research tool for creating interactive custom maps which amalgamate MetaBase knowledge content with proprietary information and data.
Julie Bryant, GeneGo’s vice president of business development, said: “We have a good working relationship with GSK developing new products such as our pay as you go 1-2-3 Workflow. We will continue to work closely developing new functionality, tools and content for GSK.”